The Cystic Fibrosis Foundation today announced the official opening of its one-of-a kind cystic fibrosis research facility, based in Lexington, Mass. The lab is designed to identify and test potential therapies for CF, readying them for further development with the ultimate goal of bringing new drugs to people living with the disease.
Operated by Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), an affiliate of the CF Foundation, the lab has a team of 25 employees who focus on finding promising drugs for both common and rare mutations of the cystic fibrosis transmembrane conductance regulator (
“Our goal is to speed the development of new treatments for all people with cystic fibrosis,” said William Skach, M.D., senior vice president for research affairs at the CF Foundation. “The lab provides a unique bridge to fill the gap between academic discovery and the pharmaceutical industry in advancing CF therapies.”
CF is a complex disease that is caused by more than 1,700 genetic mutations in the
Building on its expertise in
Meanwhile, the lab will continue its work